Structure Control 1 Control 2 Control 3 Control 4 Control 5 Control 6 Control 7 Control 8 Hepatoma 1 Hepatoma 2 Hepatoma 3 Hepatoma 4 A4G4 0.42 0.18 0.41 0.57 0.55 0.49 0.50 0.41 0.41 1.13 0.64 0.13 A4G4F 0.23 0.35 0.33 0.39 0.42 0.26 0.27 0.21 0.54 0.10 0.17 0.28 A4G4Fo 0.19 0.10 0.14 0.11 0.15 0.10 0.40 0.10 0.08 0.10 0.02 0.28 A3G3 0.06 0.04 0.05 0.01 0.02 0.08 0.04 0.07 0.03 0.07 0.07 0.02 A3G2G'1(4) 1.40 1.18 1.70 2.21 1.57 1.67 0.97 1.24 0.38 1.18 3.15 0.80 A3G3F 0.88 0.73 0.77 0.38 0.56 0.62 0.47 0.39 1.00 0.19 0.29 0.73 A3G3Fo 0.92 1.04 0.87 0.61 0.54 0.60 0.63 0.74 0.87 0.17 0.33 0.49 A'3G3 0.34 0.17 0.38 0.48 0.16 0.27 0.43 0.33 0.33 0.64 0.19 0.39 A'3G3F 0.55 0.53 0.51 0.32 0.32 0.38 0.27 0.45 0.31 0.12 0.23 0.76 GnT V products 1.72 1.33 0.89 1.88 1.61 1.50 1.88 1.44 1.69 2.10 1.26 1.84 GnT IV products 4.10 3.63 4.27 4.29 3.83 3.82 3.28 3.17 2.42 2.94 4.68 2.72

Table 3: Amount of triantennary and tetraantennary N-glycans expressed in human hepatocellular carcinomas and non-pathological regions of human liver. N-glycan expressed in non-pathological regions of eight tumor-bearing patient livers dissected during the operation (Control) and four dissected hepatocellular carcinomas were analyzed. The table shows the amounts of triantennary and four antennary N-glycans expressed in these tissues in terms of the percentages of the total amount of N-glycans.